beta-Lactamases

"beta-Lactamases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Enzymes found in many bacteria which catalyze the hydrolysis of the amide bond in the beta-lactam ring. Well known antibiotics destroyed by these enzymes are penicillins and cephalosporins.

Descriptor ID	D001618
MeSH Number(s)	D08.811.277.087.180
Concept/Terms	beta-Lactamases beta-Lactamases beta Lactamases beta-Lactamase beta Lactamase

Below are MeSH descriptors whose meaning is more general than "beta-Lactamases".

Chemicals and Drugs [D]
Enzymes and Coenzymes [D08]
Enzymes [D08.811]
Hydrolases [D08.811.277]
Amidohydrolases [D08.811.277.087]
beta-Lactamases [D08.811.277.087.180]

Below are MeSH descriptors whose meaning is related to "beta-Lactamases".

Below are MeSH descriptors whose meaning is more specific than "beta-Lactamases".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "beta-Lactamases" by people in this website by year, and whether "beta-Lactamases" was a major or minor topic of these publications.

Bar chart showing 90 publications over 24 distinct years, with a maximum of 12 publications in 2023

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1998	3	0	3
1999	1	1	2
2000	0	1	1
2002	3	2	5
2003	1	1	2
2004	0	3	3
2006	3	0	3
2007	1	0	1
2008	0	1	1
2009	0	1	1
2010	4	0	4
2011	0	1	1
2013	2	0	2
2014	1	1	2
2015	3	2	5
2016	4	3	7
2017	2	3	5
2018	1	8	9
2019	0	6	6
2020	0	2	2
2021	1	2	3
2022	2	5	7
2023	0	12	12
2024	0	3	3

Below are the most recent publications written about "beta-Lactamases" by people in Profiles.

Karlowsky JA, Wise MG, Hackel MA, Six DA, Uehara T, Daigle DM, Pevear DC, Moeck G, Sahm DF. Cefepime-taniborbactam activity against antimicrobial-resistant clinical isolates of Enterobacterales and Pseudomonas aeruginosa: GEARS global surveillance programme 2018-22. J Antimicrob Chemother. 2024 12 02; 79(12):3116-3131.

View in: PubMed
Karlowsky JA, Lob SH, Hawser SP, Kothari N, Siddiqui F, Alekseeva I, DeRyke CA, Young K, Motyl MR, Sahm DF. Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Greece and Italy-SMART 2017-2021. Eur J Clin Microbiol Infect Dis. 2024 Jul; 43(7):1343-1348.

View in: PubMed
Wise MG, Karlowsky JA, Mohamed N, Hermsen ED, Kamat S, Townsend A, Brink A, Soriano A, Paterson DL, Moore LSP, Sahm DF. Global trends in carbapenem- and difficult-to-treat-resistance among World Health Organization priority bacterial pathogens: ATLAS surveillance program 2018-2022. J Glob Antimicrob Resist. 2024 06; 37:168-175.

View in: PubMed
Gill CM, Rajkotia P, Roberts AL, Tenover FC, Nicolau DP. Directed carbapenemase testing is no longer just for Enterobacterales: cost, labor, and workflow assessment of expanding carbapenemase testing to carbapenem-resistant P. aeruginosa. Emerg Microbes Infect. 2023 Dec; 12(1):2179344.

View in: PubMed
Wise MG, Karlowsky JA, Chen WT, Siddiqui F, Young K, Motyl MR, Sahm DF. Susceptibility of gram-negative isolates collected in Taiwan to imipenem/relebactam and comparator agents - SMART 2018-2021. J Formos Med Assoc. 2024 Mar; 123(3):400-407.

View in: PubMed
Wise MG, Karlowsky JA, Hackel MA, Harti MA, Ntshole BME, Njagua EN, Oladele R, Samuel C, Khan S, Wadula J, Lowman W, Lembede BW, Sahm DF. In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa from sub-Saharan Africa: ATLAS Global Surveillance Program 2017-2021. J Glob Antimicrob Resist. 2023 12; 35:93-100.

View in: PubMed
Wise MG, Karlowsky JA, Mohamed N, Kamat S, Sahm DF. In vitro activity of aztreonam-avibactam against Enterobacterales isolates collected in Latin America, Africa/Middle East, Asia, and Eurasia for the ATLAS Global Surveillance Program in 2019-2021. Eur J Clin Microbiol Infect Dis. 2023 Sep; 42(9):1135-1143.

View in: PubMed
Gales AC, Stone G, Sahm DF, Wise MG, Utt E. Incidence of ESBLs and carbapenemases among Enterobacterales and carbapenemases in Pseudomonas aeruginosa isolates collected globally: results from ATLAS 2017-2019. J Antimicrob Chemother. 2023 07 05; 78(7):1606-1615.

View in: PubMed
Karlowsky JA, Lob SH, Chen WT, DeRyke CA, Siddiqui F, Young K, Motyl MR, Sahm DF. In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in the Asia-Pacific region: SMART 2017-2020. Int J Antimicrob Agents. 2023 Sep; 62(3):106900.

View in: PubMed
Wise MG, Karlowsky JA, Hackel MA, Takemura M, Yamano Y, Echols R, Sahm DF. In Vitro Activity of Cefiderocol Against Meropenem-Nonsusceptible Gram-Negative Bacilli with Defined ?-Lactamase Carriage: SIDERO-WT Surveillance Studies, 2014-2019. Microb Drug Resist. 2023 Aug; 29(8):360-370.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement